Mikio Sugimoto

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 357 citations

Urology, Genitourinary Cancer, Medicine +8

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 256 citations · Full text

Urology, Oncology, Genitourinary Cancer +8

Evidenced‐based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition)

Yoshiyuki Kakehi, Mikio Sugimoto, Rikiya Taoka · International Journal of Urology · 2017 · 151 citations · Full text

Renal cell carcinoma in patients with end‐stage renal disease: relationship between histological type and duration of dialysis

Mohammed Ahmed Abdel‐Muneem Nouh, Naoto Kuroda, Motoki Yamashita et al. · British Journal of Urology · 2009 · 102 citations

Expression of Autotaxin and Acylglycerol kinase in prostate cancer: Association with cancer development and progression

Mohammed Nouh, Xiu‐Xian Wu, Homare Okazoe et al. · Cancer Science · 2009 · 94 citations · Full text